- SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS
-
Disclosed are a substituted phenylpropenylpyridine derivative, a preparation method therefor and the use thereof as a PD-1/PD-L1 inhibitor. In particular, disclosed are a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, a preparation method therefor and the use thereof. The definition of each group in the formula is detailed in the description and claims.
- -
-
-
- HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE
-
The application is directed to compounds of formulae (IA) and (IB) and their salts and solvates, wherein R1a, R2a, R3a, A1, A2, A3, R1b, R2b, R3b, B1, and B2 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Gaucher's disease, and α-synucleinopathies, such as Parkinson's disease.
- -
-
Page/Page column 106
(2021/06/04)
-
- Synthesis and evaluation of novel fused pyrimidine derivatives as GPR119 agonists
-
A novel series of fused pyrimidine derivatives were designed, synthesized and evaluated as GPR119 agonists. Among them, cyclohexene fused compounds (tetrahydroquinazolines) showed greater GPR119 agonistic activities than did dihydrocyclopentapyrimidine and tetrahydropyridopyrimidine scaffolds. Analogues (16, 19, 26, 28, 42) bearing endo-N-Boc-nortropane amine and fluoro-substituted aniline exhibited better EC50 values (0.27–1.2 μM) though they appeared to be partial agonists.
- Fang, Yuanying,Xiong, Lijuan,Hu, Jianguo,Zhang, Shaokun,Xie, Saisai,Tu, Liangxing,Wan, Yang,Jin, Yi,Li, Xiang,Hu, Shaojie,Yang, Zunhua
-
p. 103 - 111
(2019/01/28)
-
- NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
-
The present invention provides novel compounds having the general formula: wherein R1, R2 and R3 are as described herein, compositions including the compounds and methods of using the compounds.
- -
-
-
- SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS
-
Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CR4 or N; Y is CR4 or N, provided that Y is N only if X is N; R1 is Formulae (A) or (B); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, R3, R4, L1, R1a, R1b, R1c, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
- -
-
Page/Page column 56; 57
(2017/11/15)
-
- GLYCOSIDASE INHIBITORS
-
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
- -
-
Page/Page column 112; 113
(2017/09/15)
-
- GLYCOSIDASE INHIBITORS
-
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
- -
-
Page/Page column 97-98
(2017/09/15)
-
- Tetrahydropyridine [4,3-d] miazines Hsp90 inhibitor and medical application thereof
-
The invention discloses a tetrahydropyridine [4,3-d] miazines Hsp90 inhibitor and medical application thereof, and relates to the field of medicinal chemistry, in particular to a compound (I) with Hsp90 inhibition activity, and application of the compound (I) to treatment of diseases such as cancers or other proliferative diseases caused by Hsp90 abnormity. The invention further discloses a preparation method of the inhibitor.
- -
-
-
- Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90
-
Heat shock protein 90 (Hsp90) is a potential target for oncology therapeutics. Some inhibitors have shown antitumor effects in clinical trials, spurring the discovery of small molecule Hsp90 inhibitors. Here, we describe the structural optimization studies of a hit compound, tetrahydropyrido[4,3-d]pyrimidine-based Hsp90 inhibitor 15, which exhibits inhibitory activity against Hsp90. A series of analogues were synthesized, and their structure-activity and structure-property relationships were analyzed. These explorations led to the discovery of compound 73, which exhibited potent in vitro activities, good physicochemical properties, favorable ADME properties, and a potent antitumor effect in an HCT116 xenograft model. Furthermore, 73 exhibited no ocular toxicity in a rat retinal damage model, suggesting it is a relatively safe Hsp90 inhibitor. As a promising antitumor agent, 73 was progressed for further preclinical evaluation.
- Jiang, Fen,Wang, Hui-Jie,Jin, Yu-Hui,Zhang, Qiong,Wang, Zhi-Hui,Jia, Jian-Min,Liu, Fang,Wang, Lei,Bao, Qi-Chao,Li, Dong-Dong,You, Qi-Dong,Xu, Xiao-Li
-
p. 10498 - 10519
(2016/12/16)
-
- Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)
-
The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin-proteasome system (UPS) mediated protein degradation, endoplasmic reticulum-associated degradation (ERAD), and autophagy. Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-5083. Treatment of tumor cells with 71 leads to significant accumulation of markers associated with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell death. In tumor bearing mice, oral administration of 71 causes rapid accumulation of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to sustained antitumor activity in in vivo xenograft models of both solid and hematological tumors. 71 has been taken into phase 1 clinical trials in patients with multiple myeloma and solid tumors.
- Zhou, Han-Jie,Wang, Jinhai,Yao, Bing,Wong, Steve,Djakovic, Stevan,Kumar, Brajesh,Rice, Julie,Valle, Eduardo,Soriano, Ferdie,Menon, Mary-Kamala,Madriaga, Antonett,Kiss Von Soly, Szerenke,Kumar, Abhinav,Parlati, Francesco,Yakes, F. Michael,Shawver, Laura,Le Moigne, Ronan,Anderson, Daniel J.,Rolfe, Mark,Wustrow, David
-
p. 9480 - 9497
(2016/01/12)
-
- Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening
-
Rapid Overlay of Chemical Structures (ROCS), which can rapidly identify potentially active compounds by shape comparison, is recognized as a powerful virtual screening tool. By ROCS, a class of novel Hsp90 inhibitors was identified. The calculated binding mode of the most potent hit 36 guided us to design and synthesize a series of analogs (57a-57h). Over 100-fold improvement was achieved in the target-based assay. The most potent compound 57h inhibited Hsp90 with IC50 0.10 ± 0.01 μM. It also showed much improved cell potency and ligand efficiency. Our study showed that ROCS is efficient in the identification of novel cores of Hsp90 inhibitors. 57h can be ideal leads for further optimization.
- Sun, Hao-Peng,Jia, Jian-Min,Jiang, Fen,Xu, Xiao-Li,Liu, Fang,Guo, Xiao-Ke,Cherfaoui, Bahidja,Huang, Hao-Ze,Pan, Yang,You, Qi-Dong
-
p. 399 - 412
(2014/05/06)
-
- FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
-
Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.
- -
-
Page/Page column 172
(2014/02/15)
-
- Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity
-
Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. Each series produced compounds with Ki 500-fold sel
- Koehler, Michael F. T.,Bergeron, Philippe,Blackwood, Elizabeth,Bowman, Krista K.,Chen, Yung-Hsiang,Deshmukh, Gauri,Ding, Xiao,Epler, Jennifer,Lau, Kevin,Lee, Leslie,Liu, Lichuan,Ly, Cuong,Malek, Shiva,Nonomiya, Jim,Oeh, Jason,Ortwine, Daniel F.,Sampath, Deepak,Sideris, Steve,Trinh, Lan,Truong, Tom,Wu, Jiansheng,Pei, Zhonghua,Lyssikatos, Joseph P.
-
p. 10958 - 10971
(2013/02/25)
-
- PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR ITCH
-
The present invention provides an agent for prevention and/or treatment of itching comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R1 represents substituted or unsubstituted lower alkyl, etc.; R2 represents hydrogen, substituted or unsubstituted lower alkyl, etc.; R3 and R4 are the same or different and each represents hydrogen, lower alkyl, etc.; n represents 0 or 1; X represents -(CH2)2-, etc.; and Y represents the formula (II); (wherein W represents CH or a nitrogen atom; Z1 and Z2 are the same or different and each represents hydrogen, substituted or unsubstituted lower alkyl, etc.; and Z3 represents hydrogen, substituted or unsubstituted lower alkyl, etc.)]
- -
-
-
- PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR ASTHMA
-
The present invention provides an agent for prevention and/or treatment of asthma comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides an agent for prevention and/or treatment of asthma which comprises a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R1 represents a substituted or unsubstituted lower alkyl, or the like; R2 represents hydrogen, a substituted or unsubstituted lower alkyl, or the like; R3 and R4 are the same or different and each represents hydrogen, lower alkyl, or the like; n represents 0 or 1; X represents -(CH2)2-, or the like; and Y represents the formula (II) (wherein W represents CH or a nitrogen atom; Z1 and Z2 are the same or different and each represents hydrogen, a substituted or unsubstituted lower alkyl, or the like; and Z3 represents hydrogen, a substituted or unsubstituted lower alkyl, or the like)] as an active ingredient.
- -
-
Page/Page column 61
(2010/02/11)
-